Medilink Therapeutics Funding: $120M Raised, Series B (2022)
Medilink Therapeutics is based in Suzhou, China. It has raised $120M in total funding. Latest round: Series B.
Medilink Therapeutics funding overview
Medilink Therapeutics is based in Suzhou, China. Medilink Therapeutics has raised $120M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2022. The round record for Medilink Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include LYFE Capital, Qiming Venture Partners, Legend Capital, Loyal Valley Capital, Highlight Capital, Apricot Capital. 6 distinct backers are named across the disclosed rounds.
Medilink Therapeutics at a glance
Total raised
$120M
Latest round
Series B
Latest round date
March 2022
Headquarters
Suzhou, China
Notable investors
LYFE Capital, Qiming Venture Partners, Legend Capital, Loyal Valley Capital, Highlight Capital, Apricot Capital
Frequently asked about Medilink Therapeutics funding
How much has Medilink Therapeutics raised?
Medilink Therapeutics has raised $120M in total disclosed funding across the rounds on record.
Who has invested in Medilink Therapeutics?
LYFE Capital, Qiming Venture Partners, Legend Capital, Loyal Valley Capital, Highlight Capital, Apricot Capital are named among the investors backing Medilink Therapeutics.
What was the latest Medilink Therapeutics funding round?
The most recent disclosed round is a Series B, announced in March 2022.
Where is Medilink Therapeutics based?
Medilink Therapeutics is based in Suzhou, China.
When did Medilink Therapeutics last raise?
The last disclosed Medilink Therapeutics round closed in March 2022 at Series B.
Medilink Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Suzhou below to benchmark round size and investor mix.
